Menu Search
Equities

Gensight Biologics SA

SIGHT:PAR

Gensight Biologics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.305
  • Today's Change-0.003 / -0.97%
  • Shares traded155.07k
  • 1 Year change-44.24%
  • Beta2.0334
Data delayed at least 15 minutes, as of Nov 12 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform0
Hold2
Sell1
Strong Sell0

Share price forecast in EUR

The 2 analysts offering 12 month price targets for Gensight Biologics SA have a median target of 0.40, with a high estimate of 0.40 and a low estimate of 0.40. The median estimate represents a 31.15% increase from the last price of 0.305.
High31.1%0.40
Med31.1%0.40
Low31.1%0.40

Earnings history & estimates in EUR

Gensight Biologics SA reported annual 2023 losses of -0.600 per share on Mar 22, 2024.
Average growth rate+12.50%
More ▼

Revenue history & estimates in EUR

GenSight Biologics S.A. had revenues for the full year 2023 of 3.00m. This was 38.78% below the prior year's results.
Average growth rate-5.03%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.